{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:28:12Z","timestamp":1759228092819,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21 AI108529"],"award-info":[{"award-number":["R21 AI108529"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["R01EB000858"],"award-info":[{"award-number":["R01EB000858"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK095728"],"award-info":[{"award-number":["DK095728"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s11095-019-2604-9","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T19:42:29Z","timestamp":1553715749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antiretroviral Hydrophobic Core Graft-Copolymer Nanoparticles: The Effectiveness against Mutant HIV-1 Strains and in Vivo Distribution after Topical Application"],"prefix":"10.1007","volume":"36","author":[{"given":"Anita","family":"Leporati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elijah","family":"Bolotin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina B.","family":"Gottikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4806-5869","authenticated-orcid":false,"given":"Alexei A.","family":"Bogdanov Jr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"key":"2604_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.biochem.67.1.1","volume":"67","author":"AD Frankel","year":"1998","unstructured":"Frankel AD, Young JA. HIV-1: fifteen proteins and an RNA. Annu Rev Biochem. 1998;67:1\u201325.","journal-title":"Annu Rev Biochem"},{"key":"2604_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1146\/annurev.bi.63.070194.001025","volume":"63","author":"RA Katz","year":"1994","unstructured":"Katz RA, Skalka AM. The retroviral enzymes. Annu Rev Biochem. 1994;63:133\u201373.","journal-title":"Annu Rev Biochem"},{"issue":"4","key":"2604_CR3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2174\/1389200043335487","volume":"5","author":"M Witvrouw","year":"2004","unstructured":"Witvrouw M, Van Maele B, Vercammen J, Hantson A, Engelborghs Y, De Clercq E, et al. Novel inhibitors of HIV-1 integration. Curr Drug Metab. 2004;5(4):291\u2013304.","journal-title":"Curr Drug Metab"},{"issue":"9","key":"2604_CR4","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2174\/1568026043388448","volume":"4","author":"NJ Anthony","year":"2004","unstructured":"Anthony NJ. HIV-1 integrase: a target for new AIDS chemotherapeutics. Curr Top Med Chem. 2004;4(9):979\u201390.","journal-title":"Curr Top Med Chem"},{"issue":"4","key":"2604_CR5","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.clinthera.2009.04.020","volume":"31","author":"DS Schiller","year":"2009","unstructured":"Schiller DS, Youssef-Bessler M. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Clin Ther. 2009;31(4):692\u2013704.","journal-title":"Clin Ther"},{"issue":"7","key":"2604_CR6","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1517\/13543780903055056","volume":"18","author":"L Garvey","year":"2009","unstructured":"Garvey L, Winston A. Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor. Expert Opin Investig Drugs. 2009;18(7):1035\u201341.","journal-title":"Expert Opin Investig Drugs"},{"key":"2604_CR7","unstructured":"PubChem Compound Database; CID=64139, \n                    https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/64139\n                    \n                   In.: National Center for Biotechnology Information. Accessed 27 Feb 2019."},{"key":"2604_CR8","unstructured":"PubChem Compound Database; CID=5277135, In.: National Center for Biotechnology Information\n                    https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/5277135\n                    \n                  . Accessed 27 Feb 2019."},{"issue":"1","key":"2604_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-006-9132-0","volume":"24","author":"VP Torchilin","year":"2007","unstructured":"Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007;24(1):1\u201316.","journal-title":"Pharm Res"},{"key":"2604_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ejpb.2016.12.019","volume":"113","author":"M Cagel","year":"2017","unstructured":"Cagel M, Tesan FC, Bernabeu E, Salgueiro MJ, Zubillaga MB, Moretton MA, et al. Polymeric mixed micelles as nanomedicines: achievements and perspectives. Eur J Pharm Biopharm. 2017;113:211\u201328.","journal-title":"Eur J Pharm Biopharm"},{"key":"2604_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.biomaterials.2018.03.054","volume":"170","author":"JR Upponi","year":"2018","unstructured":"Upponi JR, Jerajani K, Nagesha DK, Kulkarni P, Sridhar S, Ferris C, et al. Polymeric micelles: Theranostic co-delivery system for poorly water-soluble drugs and contrast agents. Biomaterials. 2018;170:26\u201336.","journal-title":"Biomaterials."},{"issue":"4","key":"2604_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/QAD.0000000000001349","volume":"31","author":"S Mandal","year":"2017","unstructured":"Mandal S, Prathipati PK, Kang G, Zhou Y, Yuan Z, Fan W, et al. Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission. AIDS. 2017;31(4):469\u201376.","journal-title":"AIDS."},{"key":"2604_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.actbio.2016.08.018","volume":"44","author":"A Machado","year":"2016","unstructured":"Machado A, Cunha-Reis C, Araujo F, Nunes R, Seabra V, Ferreira D, et al. Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system. Acta Biomater. 2016;44:332\u201340.","journal-title":"Acta Biomater"},{"issue":"12","key":"2604_CR14","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1021\/acs.molpharmaceut.5b00544","volume":"12","author":"Y Jiang","year":"2015","unstructured":"Jiang Y, Cao S, Bright DK, Bever AM, Blakney AK, Suydam IT, et al. Nanoparticle-based ARV drug combinations for synergistic inhibition of cell-free and cell-cell HIV transmission. Mol Pharm. 2015;12(12):4363\u201374.","journal-title":"Mol Pharm"},{"issue":"4","key":"2604_CR15","doi-asserted-by":"publisher","first-page":"E802","DOI":"10.1073\/pnas.1717932115","volume":"115","author":"SN Kudalkar","year":"2018","unstructured":"Kudalkar SN, Beloor J, Quijano E, Spasov KA, Lee WG, Cisneros JA, et al. From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection. Proc Natl Acad Sci U S A. 2018;115(4):E802\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2604_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1163\/156856201744425","volume":"12","author":"X Wu","year":"2001","unstructured":"Wu X, Wang N. Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic\/glycolic acid polymers. Part II: biodegradation. J Biomater Sci Polym Ed. 2001;12:21\u201334.","journal-title":"J Biomater Sci Polym Ed"},{"issue":"1\u20132","key":"2604_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ijpharm.2009.12.013","volume":"387","author":"AK Jain","year":"2010","unstructured":"Jain AK, Goyal AK, Mishra N, Vaidya B, Mangal S, Vyas SP. PEG-PLA-PEG block copolymeric nanoparticles for oral immunization against hepatitis B. Int J Pharm. 2010;387(1\u20132):253\u201362.","journal-title":"Int J Pharm"},{"issue":"3","key":"2604_CR18","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s11095-008-9765-2","volume":"26","author":"AS Ham","year":"2009","unstructured":"Ham AS, Cost MR, Sassi AB, Dezzutti CS, Rohan LC. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res. 2009;26(3):502\u201311.","journal-title":"Pharm Res"},{"key":"2604_CR19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/1471-2334-9-198","volume":"9","author":"CJ Destache","year":"2009","unstructured":"Destache CJ, Belgum T, Christensen K, Shibata A, Sharma A, Dash A. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis. 2009;9:198.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"2604_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jconrel.2012.06.008","volume":"162","author":"JM Steinbach","year":"2012","unstructured":"Steinbach JM, Weller CE, Booth CJ, Saltzman WM. Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection. J Control Release. 2012;162(1):102\u201310.","journal-title":"J Control Release"},{"issue":"1\u20132","key":"2604_CR21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.ijpharm.2012.07.070","volume":"436","author":"D Belletti","year":"2012","unstructured":"Belletti D, Tosi G, Forni F, Gamberini MC, Baraldi C, Vandelli MA, et al. Chemico-physical investigation of tenofovir loaded polymeric nanoparticles. Int J Pharm. 2012;436(1\u20132):753\u201363.","journal-title":"Int J Pharm"},{"issue":"3","key":"2604_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ejpb.2008.09.022","volume":"71","author":"L Serra","year":"2009","unstructured":"Serra L, Domenech J, Peppas NA. Engineering design and molecular dynamics of mucoadhesive drug delivery systems as targeting agents. Eur J Pharm Biopharm. 2009;71(3):519\u201328.","journal-title":"Eur J Pharm Biopharm"},{"key":"2604_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jconrel.2014.10.026","volume":"197","author":"K Maisel","year":"2015","unstructured":"Maisel K, Ensign L, Reddy M, Cone R, Hanes J. Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse. J Control Release. 2015;197:48\u201357.","journal-title":"J Control Release"},{"issue":"Pt A","key":"2604_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99(Pt A):28\u201351.","journal-title":"Adv Drug Deliv Rev"},{"key":"2604_CR25","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jconrel.2014.04.033","volume":"190","author":"LM Ensign","year":"2014","unstructured":"Ensign LM, Cone R, Hanes J. Nanoparticle-based drug delivery to the vagina: a review. J Control Release. 2014;190:500\u201314.","journal-title":"J Control Release"},{"issue":"6","key":"2604_CR26","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1128\/AAC.00450-16","volume":"60","author":"CJ Destache","year":"2016","unstructured":"Destache CJ, Mandal S, Yuan Z, Kang G, Date AA, Lu W, et al. Topical Tenofovir Disoproxil fumarate nanoparticles prevent HIV-1 vaginal transmission in a humanized mouse model. Antimicrob Agents Chemother. 2016;60(6):3633\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2604_CR27","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.nano.2011.01.017","volume":"7","author":"DA Chiappetta","year":"2011","unstructured":"Chiappetta DA, Facorro G, de Celis ER, Sosnik A. Synergistic encapsulation of the anti-HIV agent efavirenz within mixed poloxamine\/poloxamer polymeric micelles. Nanomedicine. 2011;7(5):624\u201337.","journal-title":"Nanomedicine."},{"issue":"1","key":"2604_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2217\/nnm.09.90","volume":"5","author":"DA Chiappetta","year":"2010","unstructured":"Chiappetta DA, Hocht C, Taira C, Sosnik A. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected]. Nanomedicine (Lond). 2010;5(1):11\u201323.","journal-title":"Nanomedicine (Lond)"},{"key":"2604_CR29","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s11095-011-0542-2","volume":"29","author":"G Castillo","year":"2012","unstructured":"Castillo G, Reichstetter S, Bolotin E. Extending residence time and stability of peptides by protected graft copolymer (PGC) excipient: GLP-1 example. Pharm Res. 2012;29:306\u201318.","journal-title":"Pharm Res"},{"issue":"6","key":"2604_CR30","first-page":"553","volume":"2","author":"AJ Bogdanov","year":"2012","unstructured":"Bogdanov AJ, Mazzanti M, Castillo G. Bolotin E. Protected graft copolymer (PGC) in imaging and therapy: a platform for the delivery of covalently and non-covalently bound drugs Theranostics. 2012;2(6):553\u201376.","journal-title":"Protected graft copolymer (PGC) in imaging and therapy: a platform for the delivery of covalently and non-covalently bound drugs Theranostics"},{"issue":"8","key":"2604_CR31","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/j.nano.2016.07.004","volume":"12","author":"A Leporati","year":"2016","unstructured":"Leporati A, Novikov MS, Valuev-Elliston VT, Korolev SP, Khandazhinskaya AL, Kochetkov SN, et al. Hydrophobic-core PEGylated graft copolymer-stabilized nanoparticles composed of insoluble non-nucleoside reverse transcriptase inhibitors exhibit strong anti-HIV activity. Nanomedicine. 2016;12(8):2405\u201313.","journal-title":"Nanomedicine."},{"issue":"3","key":"2604_CR32","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s11095-012-0904-4","volume":"30","author":"S Reichstetter","year":"2013","unstructured":"Reichstetter S, Castillo GM, Rubinstein I, Nishimoto-Ashfield A, Lai M, Jones CC, et al. Protected graft copolymer excipient leads to a higher acute maximum tolerated dose and extends residence time of vasoactive intestinal peptide significantly better than sterically stabilized micelles. Pharm Res. 2013;30(3):670\u201382.","journal-title":"Pharm Res"},{"key":"2604_CR33","unstructured":"Chemical Computing Group Inc. SSW, Suite #910, Montreal, QC, Canada, H3A 2R7. Molecular Operating Environment (MOE). Inc.; 2017."},{"key":"2604_CR34","volume-title":"AMBER 2016","author":"D Case","year":"2016","unstructured":"Case D, Betz R, Botello-Smith W, Cerutti D, Cheatham T, Darden T, et al. AMBER 2016. San Francisco CA: In. University of California; 2016."},{"issue":"4","key":"2604_CR35","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s11095-011-0646-8","volume":"29","author":"S Reichstetter","year":"2012","unstructured":"Reichstetter S, Castillo GM, Lai MS, Nishimoto-Ashfield A, Banerjee A, Bogdanov A, et al. Protected graft copolymer (PGC) basal formulation of insulin as potentially safer alternative to LantusA (R) (insulin-glargine): a Streptozotocin-induced, diabetic Sprague Dawley rats study. Pharm Res. 2012;29(4):1033\u20139.","journal-title":"Pharm Res"},{"issue":"138","key":"2604_CR36","doi-asserted-by":"publisher","first-page":"138ra179","DOI":"10.1126\/scitranslmed.3003453","volume":"4","author":"LM Ensign","year":"2012","unstructured":"Ensign LM, Tang BC, Wang YY, Tse TA, Hoen T, Cone R, et al. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med. 2012;4(138):138ra179.","journal-title":"Sci Transl Med"},{"key":"2604_CR37","doi-asserted-by":"crossref","unstructured":"Caligioni CS. Assessing reproductive status\/stages in mice. Curr Protoc Neurosci. 2009;Appendix 4:Appendix 4I.","DOI":"10.1002\/0471142301.nsa04is48"},{"issue":"1","key":"2604_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1021\/bc5005087","volume":"26","author":"AA Bogdanov Jr","year":"2015","unstructured":"Bogdanov AA Jr, Gupta S, Koshkina N, Corr SJ, Zhang S, Curley SA, et al. Gold nanoparticles stabilized with MPEG-grafted poly(l-lysine): in vitro and in vivo evaluation of a potential theranostic agent. Bioconjug Chem. 2015;26(1):39\u201350.","journal-title":"Bioconjug Chem"},{"issue":"6445","key":"2604_CR39","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/365451a0","volume":"365","author":"BA Larder","year":"1993","unstructured":"Larder BA, Kellam P, Kemp SD. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature. 1993;365(6445):451\u20133.","journal-title":"Nature."},{"issue":"9","key":"2604_CR40","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1128\/JVI.65.9.4887-4892.1991","volume":"65","author":"JH Nunberg","year":"1991","unstructured":"Nunberg JH, Schleif WA, Boots EJ, O'Brien JA, Quintero JC, Hoffman JM, et al. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol. 1991;65(9):4887\u201392.","journal-title":"J Virol"},{"issue":"3","key":"2604_CR41","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/QAI.0000000000000172","volume":"66","author":"D Donnell","year":"2014","unstructured":"Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66(3):340\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"2604_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074314","volume":"8","author":"FM Kibengo","year":"2013","unstructured":"Kibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, et al. Safety, adherence and acceptability of intermittent tenofovir\/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLoS One. 2013;8(9):e74314.","journal-title":"PLoS One"},{"issue":"12","key":"2604_CR43","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2018.1917","volume":"319","author":"J Riddell","year":"2018","unstructured":"Riddell J, Amico KR, Mayer KH. HIV Preexposure prophylaxis: a review. Jama. 2018;319(12):1261\u20138.","journal-title":"Jama."},{"issue":"6","key":"2604_CR44","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1071\/SH18103","volume":"15","author":"PS Sullivan","year":"2018","unstructured":"Sullivan PS, Siegler AJ. Getting pre-exposure prophylaxis (PrEP) to the people: opportunities, challenges and emerging models of PrEP implementation. Sex Health. 2018;15(6):522\u20137.","journal-title":"Sex Health"},{"issue":"7419","key":"2604_CR45","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nature11398","volume":"490","author":"TT Murooka","year":"2012","unstructured":"Murooka TT, Deruaz M, Marangoni F, Vrbanac VD, Seung E, von Andrian UH, et al. HIV-infected T cells are migratory vehicles for viral dissemination. Nature. 2012;490(7419):283\u20137.","journal-title":"Nature."},{"issue":"3","key":"2604_CR46","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/mi.2010.2","volume":"3","author":"E Saba","year":"2010","unstructured":"Saba E, Grivel JC, Vanpouille C, Brichacek B, Fitzgerald W, Margolis L, et al. HIV-1 sexual transmission: early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. Mucosal Immunol. 2010;3(3):280\u201390.","journal-title":"Mucosal Immunol"},{"issue":"10","key":"2604_CR47","doi-asserted-by":"publisher","first-page":"6145","DOI":"10.1128\/AAC.03591-14","volume":"58","author":"R Kulkarni","year":"2014","unstructured":"Kulkarni R, Hluhanich R, McColl DM, Miller MD, White KL. The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro. Antimicrob Agents Chemother. 2014;58(10):6145\u201350.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2604_CR48","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1128\/JCM.01291-16","volume":"55","author":"D Sacks","year":"2017","unstructured":"Sacks D, Ledwaba J, Morris L, Hunt GM. Rapid detection of common HIV-1 drug resistance mutations by use of high-resolution melting analysis and unlabeled probes. J Clin Microbiol. 2017;55(1):122\u201333.","journal-title":"J Clin Microbiol"},{"issue":"11","key":"2604_CR49","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1089\/aid.2009.0227","volume":"26","author":"AM Nel","year":"2010","unstructured":"Nel AM, Coplan P, Smythe SC, McCord K, Mitchnick M, Kaptur PE, et al. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy. HIV-negative women AIDS Res Hum Retroviruses. 2010;26(11):1181\u201390.","journal-title":"HIV-negative women AIDS Res Hum Retroviruses"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-019-2604-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-019-2604-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-019-2604-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T08:26:49Z","timestamp":1589704009000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-019-2604-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["2604"],"URL":"https:\/\/doi.org\/10.1007\/s11095-019-2604-9","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"type":"print","value":"0724-8741"},{"type":"electronic","value":"1573-904X"}],"subject":[],"published":{"date-parts":[[2019,3,27]]},"assertion":[{"value":"7 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"73"}}